Neuroprotective clinical strategies for Parkinson's disease.
Increasing knowledge of the role of brain iron in health and disease has prompted consideration of therapeutic strategies aimed at attenuating the effects of iron and its untoward oxidative consequences. The success of this approach is critically dependent on a better understanding of the pathogenesis of Parkinson's disease. The controlled trial "Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism" (DATATOP) represents a clinical strategy to detect neuroprotective effects of antioxidative interventions. Validation of reliable biological markers of nigral degeneration is central to development of therapies that exert genuine neuroprotective effects in slowing the progression and preventing the onset of Parkinson's disease.
Shoulson
I
I
Department of Neurology, University of Rochester Medical Center, NY 14642.
D004359:Drug Therapy, Combination; D006801:Humans; D007501:Iron / Q000378:metabolism; D010084:Oxidation-Reduction; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D012642:Selegiline / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D014810:Vitamin E; D012642:Selegiline; D007501:Iron